News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
Almac Group Invests to Accelerate Formulation Development Services
10/23/2013 9:07:41 AM
In Jan 2013, Almac completed the doubling of their pharmaceutical development service capabilities with the opening of a new dedicated non-GMP facility together with 2 analytical laboratories at their UK headquarters.
The new non-GMP formulation development facility offers clients greater flexibility and speed in formulation and process development, creating an environment where development work can be progressed quickly and then easily transferred to the existing GMP development facility located on the same Almac UK campus.
Although the new facility is dedicated to non-GMP work, it mirrors all the technical capabilities of Almac’s existing GMP pharmaceutical development facility, including high levels of control over environmental conditions as well as extending current capabilities in processing potent compounds with low OELs.
In parallel to the new non-GMP facility, Almac has doubled its analytical capacity with new analytical laboratories for processing the large sample sets which result from non-GMP process development work for clients who seek to better understand their processes in line with the principles of QbD.
Additionally, in response to increased client demand for preclinical and early phase clinical GMP supply, Almac have further enhanced their pharmaceutical development offering with an investment in additional Xcelodose® technology. Similar to our existing technology this additional Xcelodose® unit comes complete with an Xcelohood® providing the capability to dose potent API directly into capsules.
“Almac is continually assessing and investing in solutions to accelerate the manufacturing of our client’s clinical supplies, while ensuring quality at all times. The investments this year in the new non-GMP facility and Xcelodose equipment strengthens Almac’s position as an integrated service provider in the pharmaceutical development sector.” said John McQuaid, VP Technical Operations.
For further information on our Pharmaceutical development services, please visit us at CPhI booth # 42L08.
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to over 600 companies globally within the pharmaceutical and biotech sectors. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has organically grown over 30 years and now employs in excess of 3,300 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with US operations based in Pennsylvania, North Carolina and California.
To learn more about Almac please visit www.almacgroup.com, e-mail firstname.lastname@example.org or follow us on Twitter at https://twitter.com/AlmacGroup.
Help employers find you! Check out all the jobs and post your resume.